Workflow
Precision medicine for cancer treatment
icon
Search documents
Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
Globenewswire· 2025-07-22 11:00
Company Overview - Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [2] - The company employs the genetic principle of synthetic lethality to develop therapies targeting critical cancer-related targets [2] Financial Announcement - Tango Therapeutics will report its second quarter 2025 financial results on August 5, 2025, before the U.S. financial markets open [1] - The company has stated that it will not hold a conference call following the financial results announcement [1]
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Globenewswire· 2025-05-27 11:00
Company Overview - Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [3] - The company employs the genetic principle of synthetic lethality to develop therapies targeting critical cancer-related pathways [3] Upcoming Event - Barbara Weber, M.D., President and CEO of Tango Therapeutics, will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on June 10, 2025, from 3:20 to 3:55 PM ET [1] - The event will be available via live webcast on the company's website, with a replay accessible for 90 days post-presentation [2]
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Globenewswire· 2025-05-01 11:00
Core Viewpoint - Tango Therapeutics, Inc. is set to report its first quarter 2025 financial results on May 12, 2025, before the U.S. financial markets open, and will not hold a conference call following the announcement [1]. Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [2]. - The company employs the genetic principle of synthetic lethality to identify and develop therapies targeting critical cancer-related objectives [2].